# US 2024/0002856 A1 · Antisense nucleic acid and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002856 A1
- Document ID: US20240002856A1
- Status: Published application
- Kind: A1
- Application number: 18/037,194
- Filed: 2021-11-15
- Published: 2024-01-04
- Earliest claimed: 2020-11-30
- Assignees: Niigata University
- Applicants: Niigata University
- Inventors: Akihiro SUGAI; Osamu ONODERA
- Web page: https://patentgrep.com/patent/US20240002856A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5023: {on expression patterns}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2217/206: Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- C12N 2310/11: Antisense
- C12N 2310/3233: Morpholino-type ring
- C12N 2320/33: Alteration of splicing
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

An antisense nucleic acid targeting intron 6 of TDP-43 mRNA, and including a nucleotide sequence complementary to a sequence consisting of 10 or more consecutive bases in a target sequence, wherein the target sequence is the 96th to 330th or 400th to 530th positions of a nucleotide sequence represented by SEQ ID NO:1.

## Claims

### Claim 1

An antisense nucleic acid targeting intron 6 of TDP-43 mRNA, comprising a nucleotide sequence complementary to a sequence consisting of 10 or more consecutive bases in a target sequence, wherein
the target sequence is the 96th to 330th or 400th to 530th positions of a nucleotide sequence represented by SEQ ID NO:1.

### Claim 2 (depends on 1)

The antisense nucleic acid according to claim 1, comprising a nucleotide sequence represented by any one of SEQ ID NOS: 2 to 7.

### Claim 3 (depends on 1)

An alternative splicing enhancer of intron 6 of TDP-43 mRNA, comprising the antisense nucleic acid according to claim 1 as an active ingredient.

### Claim 4 (depends on 1)

A pharmaceutical composition, comprising the antisense nucleic acid according to claim 1 as an active ingredient, wherein the pharmaceutical composition is used for prevention or treatment of TDP-43 proteinopathy.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the TDP-43 proteinopathy is frontotemporal lobar degeneration or amyotrophic lateral sclerosis.

### Claim 6

A screening method for an alternative splicing enhancer of intron 6 of TDP-43 mRNA, comprising
culturing CSE1L-knockdown cells expressing TDP-43 mRNA in the presence of a test substance, and
quantifying splicing variants not including intron 6 and splicing variants including intron 6 among the TDP-43 mRNA in the cells, wherein
a decrease in expression level of the splicing variants including intron 6 in the presence of the test substance compared to that in the absence of the test substance indicates that the test substance is a candidate for the alternative splicing enhancer of intron 6 of TDP-43 mRNA.

### Claim 7

A screening method for a candidate compound for prevention or treatment of TDP-43 proteinopathy, comprising
culturing CSE1L-knockdown cells expressing TDP-43 mRNA in the presence of a test substance, and
quantifying splicing variants not including intron 6 and splicing variants including intron 6 among the TDP-43 mRNA in the cells, wherein
a decrease in expression level of the splicing variants including intron 6 in the presence of the test substance compared to that in the absence of the test substance indicates that the test substance is a candidate compound for prevention or treatment of TDP-43 proteinopathy.
